Immuneering Corporation — Key Metrics
4 years of history · ending 2023-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-2
Book Value Per Share
$3
Free Cash Flow Per Share
$-2
Cash Per Share
$2
Revenue Per Share
$0
OCF Per Share
$-2
Return on Equity
-53.4%
Return on Assets
-47.5%
Return on Invested Capital
-46.0%
Current Ratio
11.35
Quick Ratio
11.35
Asset Turnover
0.00
Days Sales Outstanding
14.30
Days Payables Outstanding
7281.80
R&D / Revenue
11442.5%
SBC / Revenue
1282.4%
Capex / Revenue
234.3%
Working Capital
$81M
Net Current Asset Value
$77M
Invested Capital
$91M
OCF / Net Income
0.92
FCF / Net Income
0.92
Accruals Ratio (Sloan)
-4.4%
Net Debt
$-59M
Net Debt / EBITDA
1.02
Capex Coverage
-142.87
Tangible Common Equity
$84M
TCE / Total Assets
81.4%
Goodwill / Total Assets
6.5%
NOPAT
$-46M
Cash ROIC
-49.2%
WC / Revenue
31769.1%
Capex / D&A
1.06
Reinvestment Rate
-0.0%
Asset Growth vs Revenue Growth
83.8%
Stock Price (FY-end)
$7
Market Cap
$209M
P/S Ratio
403.77
P/B Ratio
2.31
P/TB Ratio
2.50
Enterprise Value
$149M
EV / Sales
70.84
FCF Yield
-23.6%
Shareholder Yield
-2.7%
R&D Yield
19.9%
Capex Yield
0.2%
Shares Variation (YoY)
7.7%
Beta (5Y)
1.28
Cost of Equity
10.9%
52W High
$13
52W Low
$4
Trailing Return 1Y
68.2%
F-Score (Piotroski)
1.00
Z-Score (Altman)
7.28
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.